Strong Organic Sales Growth
Stryker achieved a strong organic sales growth of 9.5% for the quarter, driven by high demand across its businesses, including MedSurg, Neurotechnology, and Orthopedics.
Double-Digit EPS Growth
The company reported a double-digit adjusted EPS growth of 11.1%, despite facing tariff headwinds.
U.S. Market Performance
U.S. organic sales growth was 10.6%, with notable contributions from Vascular, Trauma, Extremities, Neuro Cranial, and Instruments businesses.
Successful Acquisitions
Stryker completed two small acquisitions: Guard Medical's NPseal products and advanced medical balloons, enhancing their orthopedic instrument offerings and Sage business, respectively.
Record Mako Installations
Achieved best ever Q3 for Mako installations in the U.S. and worldwide, strengthening the company's #1 position in U.S. hips and knees.
Raised Full Year Outlook
Stryker raised its full year 2025 outlook, expecting a second consecutive year of 100 basis points of adjusted operating margin expansion.